Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. Issue 10269 (9th January 2021)
- Record Type:
- Journal Article
- Title:
- Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial. Issue 10269 (9th January 2021)
- Main Title:
- Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a randomised controlled trial
- Authors:
- Post, René
Germans, Menno R
Tjerkstra, Maud A
Vergouwen, Mervyn D I
Jellema, Korné
Koot, Radboud W
Kruyt, Nyika D
Willems, Peter W A
Wolfs, Jasper F C
de Beer, Frits C
Kieft, Hans
Nanda, Dharmin
van der Pol, Bram
Roks, Gerwin
de Beer, Frank
Halkes, Patricia H A
Reichman, Loes J A
Brouwers, Paul J A M
van den Berg-Vos, Renske M
Kwa, Vincent I H
van der Ree, Taco C
Bronner, Irene
van de Vlekkert, Janneke
Bienfait, Henri P
Boogaarts, Hieronymus D
Klijn, Catharina J M
van den Berg, René
Coert, Bert A
Horn, Janneke
Majoie, Charles B L M
Rinkel, Gabriël J E
Roos, Yvo B W E M
Vandertop, W Peter
Verbaan, Dagmar
Post, René
Germans, Menno R.
Tjerkstra, Maud A.
Vergouwen, Mervyn D.I.
Jellema, Korné
Koot, Radboud W.
Kruyt, Nyika D.
Willems, Peter W.A.
Wolfs, Jasper F.C.
de Beer, Frits C.
Kieft, Hans
Nanda, Dharmin
van der Pol, Bram
Roks, Gerwin
de Beer, Frank
Halkes, Patricia H.A.
Reichman, Loes J.A.
Brouwers, Paul J.A.M.
van den Berg-Vos, Renske M.
Kwa, Vincent I.H.
van der Ree, Taco C.
Bronner, Irene
Bienfait, Henri P.
Boogaarts, Hieronymus D.
Klijn, Catharina J.M.
van Bilzen, Martine
Dieks, H.J.G.
de Gans, Koen
ten Holter, J.B.M.
de Kruijk, Jelle R.
Leijzer, Charlie T.J.M.
Molenaar, Delmar
van Oostenbrugge, Robbert J.
van Pamelen, Jeske
Spaander, Fianne H.M.
Vermeer, Sarah E.
van de Vlekkert, Janneke
Voorend, J. Manuela
van den Berg, René
Coert, Bert A.
Horn, Janneke
Majoie, Charles B.L.M.
Rinkel, Gabriël J.E.
Roos, Yvo B.W.E.M.
Vandertop, W. Peter
Verbaan, Dagmar
… (more) - Abstract:
- Summary: Background: In patients with aneurysmal subarachnoid haemorrhage, short-term antifibrinolytic therapy with tranexamic acid has been shown to reduce the risk of rebleeding. However, whether this treatment improves clinical outcome is unclear. We investigated whether ultra-early, short-term treatment with tranexamic acid improves clinical outcome at 6 months. Methods: In this multicentre prospective, randomised, controlled, open-label trial with masked outcome assessment, adult patients with spontaneous CT-proven subarachnoid haemorrhage in eight treatment centres and 16 referring hospitals in the Netherlands were randomly assigned to treatment with tranexamic acid in addition to care as usual (tranexamic acid group) or care as usual only (control group). Tranexamic acid was started immediately after diagnosis in the presenting hospital (1 g bolus, followed by continuous infusion of 1 g every 8 h, terminated immediately before aneurysm treatment, or 24 h after start of the medication, whichever came first). The primary endpoint was clinical outcome at 6 months, assessed by the modified Rankin Scale, dichotomised into a good (0–3) or poor (4–6) clinical outcome. Both primary and safety analyses were according to intention to treat. This trial is registered at ClinicalTrials.gov, NCT02684812 . Findings: Between July 24, 2013, and July 29, 2019, we enrolled 955 patients; 480 patients were randomly assigned to tranexamic acid and 475 patients to the control group. In theSummary: Background: In patients with aneurysmal subarachnoid haemorrhage, short-term antifibrinolytic therapy with tranexamic acid has been shown to reduce the risk of rebleeding. However, whether this treatment improves clinical outcome is unclear. We investigated whether ultra-early, short-term treatment with tranexamic acid improves clinical outcome at 6 months. Methods: In this multicentre prospective, randomised, controlled, open-label trial with masked outcome assessment, adult patients with spontaneous CT-proven subarachnoid haemorrhage in eight treatment centres and 16 referring hospitals in the Netherlands were randomly assigned to treatment with tranexamic acid in addition to care as usual (tranexamic acid group) or care as usual only (control group). Tranexamic acid was started immediately after diagnosis in the presenting hospital (1 g bolus, followed by continuous infusion of 1 g every 8 h, terminated immediately before aneurysm treatment, or 24 h after start of the medication, whichever came first). The primary endpoint was clinical outcome at 6 months, assessed by the modified Rankin Scale, dichotomised into a good (0–3) or poor (4–6) clinical outcome. Both primary and safety analyses were according to intention to treat. This trial is registered at ClinicalTrials.gov, NCT02684812 . Findings: Between July 24, 2013, and July 29, 2019, we enrolled 955 patients; 480 patients were randomly assigned to tranexamic acid and 475 patients to the control group. In the intention-to-treat analysis, good clinical outcome was observed in 287 (60%) of 475 patients in the tranexamic acid group, and 300 (64%) of 470 patients in the control group (treatment centre adjusted odds ratio 0·86, 95% CI 0·66–1·12). Rebleeding after randomisation and before aneurysm treatment occurred in 49 (10%) patients in the tranexamic acid and in 66 (14%) patients in the control group (odds ratio 0·71, 95% CI 0·48–1·04). Other serious adverse events were comparable between groups. Interpretation: In patients with CT-proven subarachnoid haemorrhage, presumably caused by a ruptured aneurysm, ultra-early, short-term tranexamic acid treatment did not improve clinical outcome at 6 months, as measured by the modified Rankin Scale. Funding: Fonds NutsOhra. … (more)
- Is Part Of:
- Lancet. Volume 397:Issue 10269(2021)
- Journal:
- Lancet
- Issue:
- Volume 397:Issue 10269(2021)
- Issue Display:
- Volume 397, Issue 10269 (2021)
- Year:
- 2021
- Volume:
- 397
- Issue:
- 10269
- Issue Sort Value:
- 2021-0397-10269-0000
- Page Start:
- 112
- Page End:
- 118
- Publication Date:
- 2021-01-09
- Subjects:
- Medicine -- Periodicals
Medicine -- Periodicals
Medicine
Medicine
Electronic journals
Periodicals
610.5 - Journal URLs:
- http://www.thelancet.com/ ↗
http://www.sciencedirect.com/science/journal/01406736 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/S0140-6736(20)32518-6 ↗
- Languages:
- English
- ISSNs:
- 0140-6736
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5146.000000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15407.xml